E138Cite as: Can Urol Assoc J 2011;5(6):E138-E141; http://dx.doi.org/10.5489/cuaj.10028. Epub 2011 Jan 13.
AbstractBackground: Angiomyolipoma (AML) is a benign renal neoplasm. First-line therapy includes renal preserving surgery or angioembolization (RAE), both with good outcomes in isolated studies. However, there are no comparative randomized trials and no clinical guidelines to help clinicians decide between these treatment modalities. Our study examines the patterns of AML treatment at a tertiary care centre to evaluate how local urologists have been treating this disease. Methods: This is a retrospective study of all AMLs treated at the Vancouver General Hospital (Vancouver, BC, Canada) over the past 10 years with either RAE or surgical excision. Searches were performed of the radiology and pathology dictation systems, using the following keywords: AML, angiomyolipoma, angioembolization, embolization, surgery, partial nephrectomy and nephrectomy. Results: At our institution, more AMLs were treated by surgery than angioembolization (42 vs. 17 cases). Angioembolization was more often chosen for cases of multifocal AML (35% vs. 7%) and acute hemorrhage (50% vs. 14%). In the angioembolization cases, particles were the embolic agent of choice (used 40% of the time). Conclusions: Angioembolization allows rapid patient stabilization in cases of acute hemorrhage, and provides good renal preservation in cases of multifocal AML. It may also be preferred in large masses when partial nephrectomy is not feasible. Surgery should be performed in cases of diagnostic uncertainty or complex vascular anatomy not amenable to RAE. Prospective randomized studies are needed to compare RAE and surgery to better define their indications in sporadic AML.
RésuméContexte : Un angiomyolipome (AML) est une tumeur bénigne du rein. Le traitement de première intention comprend une chirurgie de conservation rénale ou une angioembolisation rénale, qui ont toutes deux donné de bons résultats dans des études isolées. Cependant, aucun essai comparatif randomisé n'a été mené et il n'existe pas de lignes directrices pour aider les cliniciens à choisir entre ces modalités thérapeutiques. Notre étude a examiné les tendances dans le traitement de l'AML à un centre de soins tertiaires pour évaluer comment les urologues y traitent cette maladie.